CX Institutional Has $7.66 Million Holdings in Medtronic PLC $MDT

CX Institutional boosted its holdings in shares of Medtronic PLC (NYSE:MDT) by 12.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 79,788 shares of the medical technology company’s stock after acquiring an additional 8,960 shares during the quarter. CX Institutional’s holdings in Medtronic were worth $7,664,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Corundum Trust Company INC acquired a new stake in Medtronic during the 3rd quarter worth about $27,000. Lodestone Wealth Management LLC acquired a new stake in Medtronic during the 4th quarter worth about $27,000. Valley Wealth Managers Inc. acquired a new stake in Medtronic during the 3rd quarter worth about $29,000. Board of the Pension Protection Fund acquired a new stake in Medtronic during the 4th quarter worth about $29,000. Finally, GoalVest Advisory LLC acquired a new stake in Medtronic during the 4th quarter worth about $29,000. 82.06% of the stock is currently owned by institutional investors and hedge funds.

More Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Received CE mark for the Stealth AXiS™ surgical system (spine & cranial); management frames the system as an integrated next?generation navigation, planning and robotics platform that should help drive surgical growth and address hospital demand for consolidated systems. Medtronic plc (MDT) Receives the CE Mark for the Stealth AXiS™ Surgical System
• Positive Sentiment: CE mark in Europe for Stealth AXiS expands Medtronic’s addressable surgical market after earlier U.S. clearance — this supports the company’s surgical robotics/navigation growth story and creates new revenue opportunities in European hospitals. Medtronic’s Stealth AXiS Europe Approval Expands Surgical Growth Story
• Positive Sentiment: Progress on cardiac rhythm devices: Affera’s Sphere?9 FDA Breakthrough designation and related CE activity for ablation catheters highlight Medtronic’s expanding pulsed?field and RF ablation portfolio — could boost future electrophysiology revenue if trials and approvals continue to progress. Affera Breakthrough: FDA Nod For Sphere-9 Could Be A Game Changer For Medtronic (MDT)
• Positive Sentiment: FDA cleared a next?generation mitral valve, and Medtronic has enrolled the first patient in a post?approval study for the Altaviva tibial neuromodulation system — both items support incremental product revenue and clinical validation across cardiovascular and neuromodulation franchises. Medtronic wins FDA nod for next-gen mitral valve Medtronic enrolls first patient in post-approval study of Altaviva tibial neuromod
• Neutral Sentiment: Industry reports highlight wearable medical device market growth (Australia, Saudi Arabia) that could support long?term opportunities for Medtronic’s wearable/remote monitoring initiatives, but these are broad market trends rather than company?specific catalysts. Australia Wearable Medical Devices Market Trends and Forecasts Saudi Arabia Wearable Medical Devices Market Trends and Forecasts
• Neutral Sentiment: Competitor and sector moves — Masimo published a large real?world study on pulse oximetry accuracy across skin tones; Teleflex named a new CEO; Orchestra BioMed received another FDA Breakthrough designation. These items influence competitive and regulatory context but are not direct Medtronic earnings drivers. Masimo SET Shows Accurate Pulse Oximetry in Newborns of All Skin Tones Teleflex Appoints Jason Weidman as President and CEO FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy
• Negative Sentiment: Technical/market weakness: coverage noting MDT trading near multi?month/1?year lows highlights investor concern about valuation and near?term momentum despite the product wins — this likely contributes to downward pressure on the stock. Medtronic Near Lows: S&P 500 Index Healthcare Story to Watch

Medtronic Stock Down 1.2%

Shares of Medtronic stock opened at $80.02 on Friday. The firm has a market cap of $102.74 billion, a price-to-earnings ratio of 22.29, a P/E/G ratio of 2.08 and a beta of 0.62. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.54 and a quick ratio of 1.87. Medtronic PLC has a 52-week low of $78.91 and a 52-week high of $106.33. The stock has a 50-day simple moving average of $88.44 and a 200-day simple moving average of $94.81.

Medtronic (NYSE:MDT) last announced its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.34 by $0.02. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The business had revenue of $9.02 billion during the quarter, compared to analyst estimates of $8.89 billion. During the same period in the previous year, the company earned $1.38 EPS. The firm’s revenue was up 5.8% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, equities research analysts expect that Medtronic PLC will post 5.57 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, April 17th. Investors of record on Friday, March 27th were paid a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.5%. The ex-dividend date of this dividend was Friday, March 27th. Medtronic’s dividend payout ratio (DPR) is presently 79.11%.

Insider Buying and Selling at Medtronic

In related news, EVP Harry Skip Kiil sold 52,524 shares of the firm’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total value of $5,132,120.04. Following the transaction, the executive vice president directly owned 32,768 shares of the company’s stock, valued at approximately $3,201,761.28. This trade represents a 61.58% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.26% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. Wall Street Zen lowered Medtronic from a “buy” rating to a “hold” rating in a research report on Saturday, April 11th. Truist Financial reduced their price target on Medtronic from $103.00 to $95.00 and set a “hold” rating for the company in a report on Wednesday, April 15th. Citigroup reduced their price target on Medtronic from $117.00 to $110.00 and set a “buy” rating for the company in a report on Tuesday, April 7th. Piper Sandler reduced their price target on Medtronic from $105.00 to $91.00 and set a “neutral” rating for the company in a report on Wednesday, April 1st. Finally, JPMorgan Chase & Co. reduced their price target on Medtronic from $105.00 to $100.00 and set a “neutral” rating for the company in a report on Wednesday, February 18th. Fifteen research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $107.80.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter?defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).